BiotechTube

Ciclesonide nasal + Placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Rhinitis, Allergic, Perennial

Conditions

Rhinitis, Allergic, Perennial, Hay Fever

Trial Timeline

Sep 1, 2004 → Nov 1, 2005

NCT ID
NCT00658918

About Ciclesonide nasal + Placebo

Ciclesonide nasal + Placebo is a phase 3 stage product being developed by AstraZeneca for Rhinitis, Allergic, Perennial. The current trial status is completed. This product is registered under clinical trial identifier NCT00658918. Target conditions include Rhinitis, Allergic, Perennial, Hay Fever.

What happened to similar drugs?

20 of 20 similar drugs in Rhinitis, Allergic, Perennial were approved

Approved (20) Terminated (2) Active (0)
✅placebo, isotonic ciclesonide, hypotonic ciclesonideSumitomo PharmaApproved
✅ciclesonide nasal aerosol + ciclesonide nasal spraySumitomo PharmaApproved
✅BudesonideJohnson & JohnsonApproved
✅Cetirizine + LoratadineJohnson & JohnsonApproved
✅Budesonide + PlaceboAstraZenecaApproved
✅Ciclesonide nasal spray + placebo Azelastine + Ciclesonide nasal spray + AzelastineAstraZenecaApproved
✅Loratadine + BetamethasoneMerckApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00658918Phase 3Completed

Competing Products

20 competing products in Rhinitis, Allergic, Perennial

See all competitors
ProductCompanyStageHype Score
LY3650150 + Placebo + Standard therapy for INCSEli LillyPhase 3
47
Bilastine + Desloratadine + PlaceboYuhanPhase 3
40
ASP4070 + PlaceboAstellas PharmaPhase 2
35
S-555739 Dose 1 + S-555739 Dose 2 + Cetirizine HCl Dose 1 + S-555739 placebo + Cetirizine HCl placeboShionogiPhase 2
35
Cetirizine + High dose ONO-4053 + Low dose ONO-4053 + PlaceboOno PharmaceuticalPhase 2
35
placebo, isotonic ciclesonide, hypotonic ciclesonideSumitomo PharmaApproved
35
ciclesonide nasal aerosol + ciclesonide nasal spraySumitomo PharmaApproved
43
ciclesonide hydrofluoroalkane (HFA) nasal aerosol + mometasone nasal inhalationSumitomo PharmaPhase 3
40
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + PlaceboSumitomo PharmaPhase 3
40
ciclesonide nasal aerosol + mometasone Aqueous (AQ) nasal spraySumitomo PharmaPhase 1
29
ciclesonide + mometasoneSumitomo PharmaPhase 3
40
DSP-3025 + PlaceboSumitomo PharmaPhase 1
29
ciclesonide nasal aerosol + PlaceboSumitomo PharmaPhase 3
40
Ciclesonide HFA 80 mcg + Ciclesonide HFA 160 mcg + PlaceboSumitomo PharmaPhase 3
40
Ciclesonide HFA Nasal Aerosol 320 mcg + Ciclesonide HFA Nasal Aerosol 160 mcg + HFA Nasal Aerosol placebo + Ciclesonide Aqueous Nasal Spray 200 mcg + AQ Nasal Spray Placebo + Placebo plus Dexamethasone HFA + Placebo AQ plus Dexamethasone 6 mgSumitomo PharmaPhase 3
40
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + PlaceboSumitomo PharmaPhase 3
40
80 mcg Ciclesonide + 160 mcg Ciclesonide + PlaceboSumitomo PharmaPhase 3
40
ciclesonide HFA 160 μgSumitomo PharmaPhase 3
40
Ciclesonide HFA 160 μg + Ciclesonide HFA 80 μg + PlaceboSumitomo PharmaPhase 3
40
GSP 301-1 NS (QD) + GSP 301-2 NS (BID) + GSP 301 Placebo NS + Olopatadine HCl-1 NS (QD) + Olopatadine HCl-2 NS (BID) + Mometasone Furoate-1 NS (QD) + Mometasone Furoate-2 NS (BID)Glenmark PharmaceuticalsPhase 2
35